REG - Cambridge Cognition - £2m contract for a pivotal cancer therapy trial

Cambridge Cognition HoldingsAnnouncement

13/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230613:nRSM4676Ca&default-theme=true

RNS Number : 4676C  Cambridge Cognition Holdings PLC  13 June 2023

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition wins £2 million contract for a pivotal cancer therapy
trial

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions
to assess brain health, is pleased to announce it has won a £2 million
contract for a pivotal cancer therapy trial. The Company will provide its
proprietary cognitive assessments (CANTAB®) as an exploratory endpoint with
revenue from the contract expected to be recognised over the next five years.
 

Regulatory approvals for oncology drugs have almost tripled over the last 10
years (16 approvals in 2013 to 43 approvals in 2022)(1). With a growing number
of therapeutics available, pharmaceutical companies are now investing heavily
in differentiating their new drugs and are particularly focused on limiting
long-term side effects, such as cognitive impairment, which impacts 30% of
patients following chemotherapy(2).

Cognitive decline associated with cancer most notably affects attention,
memory, and executive function. CANTAB® offers the sensitivity and
specificity to measure these distinct cognitive processes.  Recognising this,
CANTAB® has been selected as an exploratory endpoint in this pivotal oncology
trial. Cambridge Cognition secured this contract because not only does it
offer well-validated, proprietary assessments, but a delivery platform with a
track record of successful, global deployment. Supported by the Company's
experienced clinical project management team, CANTAB® will be deployed in 9
countries and in 11 languages to accurately assess cognition across 70 trial
sites.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:

"Advances in cancer treatment have led to increased consideration for limiting
the side-effects that impact patients' quality of life. Reducing cognitive
impairment could have a major impact on patients' lives. We are pleased to be
working with a major pharmaceutical company to support their development
programme. With significant investment being made in cancer trials by the
world's leading pharmaceutical companies, we expect that this could become a
considerable growth area for Cambridge Cognition in the future."

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the
European Union (Withdrawal) Act 2018.

References

1.        GlobalData. 2023.
https://www.globaldata.com/media/pharma/globaldata-forecasts-oncology-drug-sales-to-generate-2-2-trillion-between-2023-and-2029/
(https://www.globaldata.com/media/pharma/globaldata-forecasts-oncology-drug-sales-to-generate-2-2-trillion-between-2023-and-2029/)

2.        Assessment and management of cognitive symptoms in patients
with brain tumours, Parsons & Dietrich, American Society of Clinical
Oncology Educational Book 41 (May 19, 2021)

 

Enquiries

 

 Cambridge Cognition Holdings Plc                         Tel: 012 2381 0700 

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)  

 Stephen Symonds, Chief Financial Officer 

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)     Tel: 020 7886 2500 

 Freddy Crossley / Emma Earl                              (Corporate Finance) 

 Rupert Dearden                                           (Corporate Broking) 

 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715 

 David Poutney / James Serjeant                            

 IFC Advisory Ltd (Financial PR and IR)                   Tel: 020 3934 6630 

 Tim Metcalfe / Graham Herring / Zach Cohen               cog@investor-focus.co.uk

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBRGDLLUBDGXD